中國新城鎮(01278.HK)以7.39億人幣出售土地開發附屬
中國新城鎮(01278.HK)公布,於6月30日與買方瀋陽萬潤新城投資管理訂立協議,以代價7.39億元人民幣出售附屬公司瀋陽李相新城現代農業,購買對價部分為出售股權的代價,部分將用於償還瀋陽李相新城現代農業的應付欠款。
瀋陽李相新城現代農業主要從事國有地塊的土地一級開發工作,目前並無從事房地產開發業務,亦無擁有其開展土地開發業務的土地所有權。該公司此前承接政府委託,於相關項目地區進行國有地塊的土地一級開發,然而鑒於政策變化及當地政府未能於相關項目地區落實土地建設及規劃目標,先前承接的項目已停滯,除自用辦公場所外目前並無擁有任何物業或土地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.